1,280 results on '"Jacobson, Ira"'
Search Results
152. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
153. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
154. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial
155. Optimal treatment with telaprevir for chronic HCV infection
156. Genotype 1: Standard Treatment
157. Noninvasive and Invasive Imaging of the Liver and Biliary Tract
158. Immune Modulators and Other Agents
159. Discovery and Development of Telaprevir
160. The HCV and HIV coinfected patient: What have we learned about pathophysiology?
161. Treatment of Relapsers after Combination Therapy for Chronic Hepatitis C
162. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
163. Anti-HCV Agents in Development
164. Futility rules in telaprevir combination treatment
165. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) + PR: the provide study interim results
166. Determinants of Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis: 959
167. Absolute and Relative Contraindications to Pegylatedinterferon (PEG-IFN) or Ribavirin (RBV) in the US General Patient Population with Chronic Hepatitis C (HCV): Results from US Database of Over 45,000 Patients: 945
168. The Safety of Telaprevir in the Absence of Interferon and/or Ribavirin: Analysis of On-Treatment Data from the ZENITH Trial: 786
169. Factors Associated with the Lack of Achievement of Normal ALT in Chronic Hepatitis B (CHB) Patients Treated with Tenofovir DF (TDF) for up to 5 Years: 411
170. Six Years of Treatment with Tenofovir DF for Chronic Hepatitis B Virus Infection is Safe and Well Tolerated and Associated with Sustained Virological, Biochemical and Serological Responses with no Detectable Resistance: 374
171. Once Daily Sofosbuvir (GS-7977) plus PEG/RBV: High Early Response Rates Are Maintained During Post-Treatment Follow-Up In Treatment-Naïve Patients With HCV Genotype 1, 4, and 6 Infection in the ATOMIC Study: 230
172. Evaluation of Liver And Plasma HCV RNA Kinetics And Telaprevir Levels In Genotype 1 HCV Patients Treated With Telaprevir (TVR) Using Serial Fine Needle Aspirates (FNA): 215
173. Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon α-2a (40KD) (P) and ribavirin (R) with or without mericitabine in HCV genotype (G)1-infected treatment-experienced patients with advanced hepatic fibrosis: 82
174. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) ± peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study: 81
175. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
176. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
177. Telaprevir userʼs guide
178. The Conundrum of Relapse in STAT-C Therapy: Does HCV Play the Red Queen or Rip Van Winkle?
179. Role of the nurse practitioner in the management of patients with chronic hepatitis C
180. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
181. Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis
182. Boceprevir for Untreated Chronic HCV Genotype 1 Infection
183. Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors
184. Machine learning identifies histologic features associated with regression of cirrhosis in treatment for chronic hepatitis B
185. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
186. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
187. PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2
188. Prevalence of Chronic Hepatitis B Virus Infection in the United States
189. Hepatitis E Virus Infection in the United States: Current Understanding of the Prevalence and Significance in the Liver Transplant Patient Population and Proposed Diagnostic and Treatment Strategies
190. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
191. The dawn of a new era: Transforming our domestic response to hepatitis B and C: Activity 7: Entering the new era of therapy for HBV and HCV infections
192. The dawn of a new era: Transforming our domestic response to hepatitis B and C: Activity 8: Transforming strategies to provide access to care
193. Research Highlights: Pharmacogenetics of hepatitis C therapy
194. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
195. New and experimental therapies for HCV
196. Diseases of the bile ducts
197. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
198. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C
199. Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B
200. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.